Swedish Orphan Biovitrum Stock Cash And Equivalents
| SOBI Stock | SEK 317.00 2.60 0.83% |
Swedish Orphan Biovitrum fundamentals help investors to digest information that contributes to Swedish Orphan's financial success or failures. It also enables traders to predict the movement of Swedish Stock. The fundamental analysis module provides a way to measure Swedish Orphan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Swedish Orphan stock.
Swedish |
Swedish Orphan Biovitrum Company Cash And Equivalents Analysis
Swedish Orphan's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Swedish Orphan Cash And Equivalents | 1.04 B |
Most of Swedish Orphan's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Swedish Orphan Biovitrum has 1.04 B in Cash And Equivalents. This is 27.3% higher than that of the Healthcare sector and 190.5% higher than that of the Drug Manufacturers - Specialty & Generic industry. The cash and equivalents for all Sweden stocks is 61.33% higher than that of the company.
Swedish Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Swedish Orphan's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Swedish Orphan could also be used in its relative valuation, which is a method of valuing Swedish Orphan by comparing valuation metrics of similar companies.Swedish Orphan is currently under evaluation in cash and equivalents category among its peers.
Swedish Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.24 % | |||
| Current Valuation | 72.79 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 70.55 % | |||
| Price To Earning | 20.29 X | |||
| Price To Book | 2.51 X | |||
| Price To Sales | 3.67 X | |||
| Revenue | 15.53 B | |||
| Gross Profit | 14.38 B | |||
| EBITDA | 5.72 B | |||
| Net Income | 2.68 B | |||
| Cash And Equivalents | 1.04 B | |||
| Cash Per Share | 4.04 X | |||
| Total Debt | 9.02 B | |||
| Debt To Equity | 39.80 % | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | 89.61 X | |||
| Cash Flow From Operations | 5.47 B | |||
| Earnings Per Share | 10.10 X | |||
| Price To Earnings To Growth | 1.98 X | |||
| Target Price | 269.56 | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.39 | |||
| Market Capitalization | 73.08 B | |||
| Total Asset | 48.66 B | |||
| Working Capital | 1.42 B | |||
| Current Asset | 2.68 B | |||
| Current Liabilities | 1.26 B | |||
| Z Score | 4.8 | |||
| Net Asset | 48.66 B |
About Swedish Orphan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Swedish Orphan Biovitrum's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Swedish Orphan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Swedish Orphan Biovitrum based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Swedish Stock Analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.